Share on StockTwits

Shares of Novartis AG (NYSE:NVS) have earned an average recommendation of “Hold” from the seven brokerages that are currently covering the company, Stock Ratings Network reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $93.50.

Several analysts have recently commented on the stock. Analysts at Barclays upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Monday. Separately, analysts at Leerink Swann raised their price target on shares of Novartis AG from $93.00 to $104.00 in a research note on Wednesday, May 28th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group upgraded shares of Novartis AG from a “hold” rating to a “buy” rating in a research note on Friday, May 2nd.

Novartis AG (NYSE:NVS) traded up 1.12% during mid-day trading on Tuesday, hitting $90.11. The stock had a trading volume of 934,377 shares. Novartis AG has a 52-week low of $67.67 and a 52-week high of $90.43. The stock’s 50-day moving average is $88.2 and its 200-day moving average is $82.80. The company has a market cap of $220.5 billion and a price-to-earnings ratio of 22.73.

Novartis AG (NYSE:NVS) last released its earnings data on Thursday, April 24th. The company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $14.02 billion for the quarter, compared to the consensus estimate of $14.25 billion. During the same quarter in the previous year, the company posted $1.32 earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Analysts expect that Novartis AG will post $5.25 EPS for the current fiscal year.

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.